Peer-reviewedPublisher termsInternational Journal of Pharmaceutics
Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS-1000) in ophthalmic liposomal formulations: friend or foe?
Related
- Oral succinate protects the heart in a temperature dependent manner in mice via gut microbiota
- 944 Succinate-based metabolic reprogramming of innate and adaptive immunity for ovarian cancer immunotherapy
- A Case of Neurohistoplasmosis Successfully Treated With Single High-Dose Liposomal Amphotericin B
- Liposomal bupivacaine versus ropivacaine thoracic paravertebral block for thoracoscopic atrial septal defect repair: analgesic efficacy and cardiac biomarker outcomes in a single-center, assessor-blinded, randomized trial
- Comparison of analgesic efficacy and safety between liposomal bupivacaine and ropivacaine for paravertebral block in patients undergoing thoracoscopic lung tumor surgery: a prospective double-blind randomized controlled trial
BibTeX
@article{pierre2026tocopheryl,
title = {{Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS-1000) in ophthalmic liposomal formulations: friend or foe?}},
author = {Mitta Pierre and Diana Lamaa and Virginie Escriou and Christine Charrueau},
journal = {International Journal of Pharmaceutics},
year = {2026},
month = sep,
doi = {10.1016/j.ijpharm.2026.127392},
url = {https://cnrs.hal.science/hal-05795116v1},
}
RIS
TY - JOUR
TI - Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS-1000) in ophthalmic liposomal formulations: friend or foe?
AU - Mitta Pierre
AU - Diana Lamaa
AU - Virginie Escriou
AU - Christine Charrueau
PY - 2026
DA - 2026/09/07
JO - International Journal of Pharmaceutics
DO - 10.1016/j.ijpharm.2026.127392
UR - https://cnrs.hal.science/hal-05795116v1
SN - 0378-5173
ER -